ImmunoPrecise Antibodies 2025年第二季度每股收益C$(0.09)超过预期C$(0.10),销售额C$6.13M未达到预期C$6.44M

财报速递
10 Dec 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)报告的季度每股亏损为$(0.09),超过了分析师一致预期的$(0.10),高出10%。与去年同期的每股亏损$(0.10)相比,这一数据增长了10%。公司报告的季度销售额为610万美元,未达到分析师一致预期的640万美元,低于预期4.88%。与去年同期的销售额615万美元相比,这一数据下降了0.41%。

以上内容来自Benzinga Earnings专栏,原文如下:

ImmunoPrecise Antibodies (NASDAQ:IPA) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 10 percent. This is a 10 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $6.13 million which missed the analyst consensus estimate of $6.44 million by 4.88 percent. This is a 0.41 percent decrease over sales of $6.15 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10